The venture financing and AMED grant funding position CORE to accelerate development of novel lineage-based oncology therapies for patients around the world. July 28, 2026 -- CORE Biomedicine, a biotechnology company pioneering lineage-based precision oncology therapeutics, today announced the completion of a $21 million Series A financing. The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, alongside participation from InnoPinnacle Fund, Mitsubishi UFJ Capital Co.,

July 27, 2026 -- Agency issues "study may proceed" letter; development pathway does not require a clinical endpoint efficacy study. DifGen Pharmaceuticals LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application and issued a "study may proceed" letter for DFGN-101, an intramuscular injection under development for the treatment of advanced or metastatic breast cancer in women. DFGN-101 is designed to be administer

July 27, 2026 -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that the Company received the U.S. Food and Drug Administration (FDA) clearance under its Regenerative Medicine Advanced Therapy (RMAT) designation regarding the multiple-center registrational Phase II clinical trial for C-CAR168, an anti-CD20/BCMA bispecific

July 27, 2026 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with China National Pharmaceutical Group Co., Ltd. ("Sinopharm"). The two parties will establish the Sinopharm - Harbour BioMed Innovation Consortium (the "Innovation Consortium") to advance collaborative research and development of inn

Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout July 27, 2026 -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity positio

July 27, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) met the primary endpoint in the registrational Phase III clinical study in patients with moderate-to-severe plaque psoriasis. The Phase III study is a randomized, double-blind, placebo-controlled, multicenter registrational clinical trial designed

Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach July 27, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a new solid tumor strategy designed to fight cancer on multiple fronts. The Company has filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone

Repligen, a Waltham, Massachusetts-based life sciences company specializing in bioprocessing technologies, has entered into a definitive agreement to acquire BioLife Solutions , a Bothell, Washington-based developer of biopreservation media and cell processing tools for the cell and gene therapy market, in a transaction valued at approximately $1.5 billion. BioLife’s biopreservation media portfolio, led by its CryoStor platform, supports 18 commercially approved therapies and the majority of U.

SIMTRIYO is the first and only norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) approved for the treatment of ADHD in adults and pediatric patients aged 6 years and older weighing at least 20kg SIMTRIYO will be commercially available later this year following scheduling by the U.S. Drug Enforcement Administration (DEA) Approval is supported by results from four pivotal Phase 3 clinical trials in adults and pediatric patients demonstrating statistically significant and clinically me

Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recomme